Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,371 | $859 | $291 | $171 |
| % Growth | 59.7% | 194.8% | 70.5% | – |
| Cost of Goods Sold | $875 | $493 | $134 | $154 |
| Gross Profit | $497 | $365 | $157 | $17 |
| % Margin | 36.2% | 42.6% | 54.1% | 10% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $483 | $366 | $327 | $419 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $483 | $366 | $327 | $419 |
| Operating Income | $14 | -$1 | -$169 | -$402 |
| % Margin | 1% | -0.1% | -58% | -235.3% |
| Other Income/Exp. Net | -$3,250 | -$2,092 | $490 | $1,661 |
| Pre-Tax Income | -$3,236 | -$2,092 | $321 | $1,259 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,236 | -$2,092 | $321 | $1,259 |
| % Margin | -236% | -243.7% | 110.2% | 737% |
| EPS | -0.016 | -0.011 | 0.002 | 0.012 |
| % Growth | -41.2% | -733.3% | -85.1% | – |
| EPS Diluted | -0.016 | -0.011 | 0.002 | 0.012 |
| Weighted Avg Shares Out | 200,719 | 182,758 | 182,163 | 104,427 |
| Weighted Avg Shares Out Dil | 200,719 | 182,758 | 182,163 | 104,427 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | $60 | $708 | $124 | $174 |
| Depreciation & Amortization | $0 | -$40 | $122 | $42 |
| EBITDA | $14 | -$1 | -$169 | -$402 |
| % Margin | 1% | -0.1% | -58% | -235.3% |